ArticlePLoS neglected tropical diseases2019
Estimating the cost of illness and burden of disease associated with the 2014-2015 chikungunya outbreak in the U.S. Virgin Islands.
Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Clinical outcomes of chikungunya across age groups: A systematic review.PLoS neglected tropical diseases · 2025Pooled it
- Burden of Chikungunya Fever and Its Economic and Social Impacts Worldwide: A Systematic Review.Tropical medicine & international health : TM & IH · 2025Pooled it
- Assessing chikungunya's economic burden and impact on health-related quality of life: Two systematic literature reviews.PLoS neglected tropical diseases · 2025Pooled it
- Compounds from Natural Products Candidates to Drug for Chikungunya Virus Infection: A Systematic Review.Current drug targets · 2024Pooled it
- Measuring the global burden of chikungunya and Zika viruses: A systematic review.PLoS neglected tropical diseases · 2021Pooled it
- Overview of Chikungunya Virus Epidemiology, Biology, and Pathogenesis.Methods in molecular biology (Clifton, N.J.) · 2027Review
- From bites to ripple effects: Unraveling the health, economic, and social effects of arboviral epidemics in Mainland France.IJID regions · 2026Article
- Identification of a TCR signature in peripheral blood derived CD4+ T cells, associated with chronic chikungunya disease, suggests a conducive, female-biased, background immune profile.Frontiers in immunology · 2026Article
- Bioisosteric and Virtual Screening Approach to Identify Natural Inhibitors of Chikunguya alphavirus nsP3.Cell biochemistry and biophysics · 2025Article
- Cost-effectiveness of chikungunya vaccination with the live attenuated vaccine in U.S. territories.NPJ vaccines · 2025Article
- Dengue diagnosis and impact on clinical management: A literature review.PLoS neglected tropical diseases · 2025Review
- Chikungunya Replication and Infection Is Dependent upon and Alters Cellular Hexosylceramide Levels in Vero Cells.Viruses · 2025Article
- One Health, many approaches: integrated vector management strategies support One Health goals.Frontiers in insect science · 2025Review
- Entomological survey to determine the role of cisterns in the production of Aedes aegypti in the U.S. Virgin Islands.PloS one · 2025Article
- The global health and economic burden of chikungunya from 2011 to 2020: a model-driven analysis on the impact of an emerging vector-borne disease.BMJ global health · 2024Article
- From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.Journal of travel medicine · 2024Review
- Distinct chikungunya virus polymerase palm subdomains contribute to viral protein accumulation and virion production.PLoS pathogens · 2024Article
- Distinct chikungunya virus polymerase palm subdomains contribute to virus replication and virion assembly.bioRxiv : the preprint server for biology · 2024Article
- Estimated annual costs of Chikungunya fever in the municipality of Rio de Janeiro, Brazil.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2024Article
- Chikungunya in Zhejiang Province, Southeast China.Infectious medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chikungunya virus (CHIKV), an alphavirus that causes fever and severe polyarthralgia, swept through the Americas in 2014 with almost 2 million suspected or confirmed cases reported by April 2016. In this study, we estimate the direct medical costs, cost of lost wages due to absenteeism, and years lived with disability (YLD) associated with the 2014-2015 CHIKV outbreak in the U.S. Virgin Islands (USVI). For this analysis, we used surveillance data from the USVI Department of Health, medical cost data from three public hospitals in USVI, and data from two studies of laboratory-positive cases up to 12 months post illness. On average, employed case-patients missed 9 days of work in the 12 months following their disease onset, which resulted in an estimated cost of $15.5 million. Estimated direct healthcare costs were $2.9 million for the first 2 months and $0.6 million for 3-12 months following the outbreak. The total estimated cost associated with the outbreak ranged from $14.8 to $33.4 million (approximately 1% of gross domestic product), depending on the proportion of the population infected with symptomatic disease, degree of underreporting, and proportion of cases who were employed. The estimated YLDs associated with long-term sequelae from the CHIKV outbreak in the USVI ranged from 599-1,322. These findings highlight the significant economic burden of the recent CHIKV outbreak in the USVI and will aid policy-makers in making informed decisions about prevention and control measures for inevitable, future CHIKV outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.